Hepatocyte growth factor gene-modified bone marrow-derived mesenchymal stem cells transplantation promotes angiogenesis in a rat model of hindlimb ischemia

Abstract

Angiogenic gene therapy and cell-based therapy for peripheral arterial disease(PAD) have been studied intensively currently. This study aimed to investigate whether combining mesenchymal stem cells(MSCs) transplantation with ex vivo human hepatocyte growth factor(HGF) gene transfer was more therapeutically efficient than the MSCs therapy alone in a rat model of hindlimb ischemia. One week after establishing hindlimb ischemia models, Sprague-Dawley(SD) rats were randomized to receive HGF gene-modified MSCs transplantation(HGF-MSC group), untreated MSCs transplantation (MSC group), or PBS injection(PBS group), respectively. Three weeks after injection, angiogenesis was significantly induced by both MSCs and HGF-MSCs transplantation, and capillary density was the highest in the HGF-MSC group. The number of transplanted cell-derived endothelial cells was greater in HGF-MSC group than in MSC group after one week treatment. The expression of angiogenic cytokines such as HGF and VEGF in local ischemic muscles was more abundant in HGF-MSC group than in the other two groups. In vitro, the conditioned media obtained from HGF-MSCs cultures exerted proproliferative and promigratory effects on endothelial cells. It is concluded that HGF gene-modified MSCs transplantation therapy may induce more potent angiogenesis than the MSCs therapy alone. Engraftment of MSCs combined with angiogenic gene delivery may be a promising therapeutic strategy for the treatment of severe PAD.

Keywords

angiogenesis / gene therapy / hepatocyte growth factor / mesenchymal stem cell / peripheral arterial disease

References

[1] BelchJJ, TopolEJ, AgnelliG, et al.. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med, 2003, 163(8): 884-892

[2] WeitzJI, ByrneJ, ClagettGP, et al.. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation, 1996, 94(11): 3026-3049

[3] BobekV, TaltynovO, PinterovaD, et al.. Gene therapy of the ischemic lower limb-Therapeutic angiogenesis. Vascul Pharmacol, 2006, 44(6): 395-405

[4] DormandyJA, RutherfordRB. Management of peripheral arterial disease(PAD). TASC Working Group. TransAtlantic Inter-Society Consensus(TASC). J Vasc Surg, 2000, 31(1Pt2): S1-S296

[5] HamouC, CallaghanMJ, ThangarajahH, et al.. Mesenchymal stem cells can participate in ischemic neovascularization. Plast Reconstr Surg, 2009, 123(2Suppl): 45S-55S

[6] Al-KhaldiA, Al-SabtiH, GalipeauJ, et al.. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Ann Thorac Surg, 2003, 75(1): 204-209

[7] KinnairdT, StabileE, BurnettMS, et al.. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation, 2004, 109(12): 1543-1549

[8] IwaseT, NagayaN, FujiiT, et al.. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res, 2005, 66(3): 543-551

[9] PicinichSC, MishraPJ, GlodJ, et al.. The therapeutic potential of mesenchymal stem cells. Cell- & tissue-based therapy. Expert Opin Biol Ther, 2007, 7(7): 965-973

[10] OzawaK, SatoK, OhI, et al.. Cell and gene therapy using mesenchymal stem cells(MSCs). J Autoimmun, 2008, 30(3): 121-127

[11] KimSW, LeeDW, YuLH, et al.. Mesenchymal stem cells overexpressing GCP-2 improve heart function through enhanced angiogenic properties in a myocardial infarction model. Cardiovasc Res, 2012, 95(4): 495-506

[12] MorishitaR, NakamuraS, HayashiS, et al.. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension, 1999, 33(6): 1379-1384

[13] WangS, QinX, SunD, et al.. Effects of hepatocyte growth factor overexpressed bone marrow-derived mesenchymal stem cells on prevention from left ventricular remodelling and functional improvement in infarcted rat hearts. Cell Biochem Funct, 2012, 30(7): 574-581

[14] ChoKR, ChoiJS, HahnW, et al.. Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg, 2008, 34(4): 857-863

[15] YuanB, ZhaoZ, ZhangYR, et al.. Short-term safety and curative effect of recombinant adenovirus carrying hepatocyte growth factor gene on ischemic cardiac disease. In Vivo, 2008, 22(5): 629-632

[16] NakamuraY, MorishitaR, NakamuraS, et al.. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension, 1996, 28(3): 409-413

[17] MatsumotoR, OmuraT, YoshiyamaM, et al.. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol, 2005, 25(6): 1168-1173

[18] KinnairdTD, StabileE, BurnettMS, et al.. HIF-1alpha/VP16 enhances the in-vitro arteriogenic potential of mesenchymal stem cells. Circulation, 2003, 108: 337A

[19] LiL, ZhangY, LiY, et al.. Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. Transpl Int, 2008, 21(12): 1181-1189

[20] DullT, ZuffereyR, KellyM, et al.. A third-generation lentivirus vector with a conditional packaging system. J Virol, 1998, 72(11): 8463-8471

[21] HoboK, ShimizuT, SekineH, et al.. Therapeutic angiogenesis using tissue engineered human smooth muscle cell sheets. Arterioscler Thromb Vasc Biol, 2008, 28(4): 637-643

[22] WangJS, Shum-TimD, GalipeauJ, et al.. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg, 2000, 120(5): 999-1005

[23] DuanHF, WuCT, WuDL, et al.. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther, 2003, 8(3): 467-474

[24] YangZJ, MaDC, WangW, et al.. Experimental study of bone marrow-derived mesenchymal stem cells combined with hepatocyte growth factor transplantation via noninfarct-relative artery in acute myocardial infarction. Gene Ther, 2006, 13(22): 1564-1568

[25] ZhaoMZ, NonoguchiN, IkedaN, et al.. Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J Cereb Blood Flow Metab, 2006, 26(9): 1176-1188

[26] GuoY, HeJ, WuJ, et al.. Locally overexpressing hepatocyte growth factor prevents post-ischemic heart failure by inhibition of apoptosis via calcineurin-mediated pathway and angiogenesis. Arch Med Res, 2008, 39(2): 179-188

[27] BianL, GuoZK, WangHX, et al.. In vitro and in vivo immunosuppressive characteristics of hepatocyte growth factor-modified murine mesenchymal stem cells. In Vivo, 2009, 23(1): 21-27

[28] NeussS, BecherE, WoltjeM, et al.. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells, 2004, 22(3): 405-414

[29] CaiL, JohnstoneBH, CookTG, et al.. Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization. Stem Cells, 2007, 25(12): 3234-3243

[30] SakonM, KitaY, YoshidaT, et al.. Plasma hepatocyte growth factor levels are increased in systemic inflammatory response syndrome. Surg Today, 1996, 26(4): 236-241

[31] Rosu-MylesM, StewartE, TrowbridgeJ, et al.. A unique population of bone marrow cells migrates to skeletal muscle via hepatocyte growth factor/c-met axis. J Cell Sci, 2005, 118Pt19: 4343-4352

[32] ForteG, MinieriM, CossaP, et al.. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells, 2006, 24(1): 23-33

[33] AokiM, MorishitaR, TaniyamaY, et al.. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther, 2000, 7(5): 417-427

[34] Van BelleE, WitzenbichlerB, ChenD, et al.. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation, 1998, 97(4): 381-390

[35] XinX, YangS, IngleG, et al.. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol, 2001, 158(3): 1111-1120

[36] ZhuXY, ZhangXZ, XuL, et al.. Transplantation of adipose-derived stem cells overexpressing hHGF into cardiac tissue. Biochem Biophys Res Commun, 2009, 379(4): 1084-1090

[37] MorishitaR. Recent progress in gene therapy for cardiovascular disease. Circ J, 2002, 66(12): 1077-1086

[38] KinnairdT, StabileE, BurnettMS, et al.. Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res, 2004, 95(4): 354-363